Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Florida
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
M.D. Anderson Cancer Center
Emory University
Eastern Cooperative Oncology Group
EMD Serono
Essen Biotech
University of Alabama at Birmingham
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Mayo Clinic
University of Nebraska
Adela, Inc
Eli Lilly and Company
Var2 Pharmaceuticals
Hoffmann-La Roche